Collaboration between antigen (Ag).specific Ic CD8 and CD4 T cells is critical for generating an effective ant-tumor I cell response, yet very little is known about where, when and how this occurs. We have developed a model that has allowed us to visualize Ag-specific T cells responding to tumor growing in vivo. The model employs adoptive transfer of CD8 T cells from 0T-I mice having a transgenic TCR specific for Kb/0VA257-264 into normal mice, and challenge with E.G7 tumor expressing OVA as a pseudo-tumor Ag. A contribution of host CD4 T cells to the response of the 0T-I cells has been demonstrated functionally, but these Ag-specific cells cannot be visualized. We are now developing a model that employs double adoptive transfer into normal mice of OT-1 CD8 T cells along with CD4 T cells from 0T-II mice having a transgenic TCR specific for I-Ad/OVA323-339. Using this model to visualize, quantitate and characterize the OVA-specific T cells during the course of a response to E.G7 tumor we will pursue four specific aims: (1) To describe the collaborative interactions that occur between Ag-specific CD8 and CD4 T cells during the course of a tumor-specific response. (2) To determine the role of CTLA-4 blockade in allowing effective anti-tumor T cell responses. (3) To examine CD8 and CD4 T cell collaboration in immunization for protection against tumor and the collaboration in the memory response. Novel immunization strategies based on recent work in our laboratory will be examined. (4) To characterize approaches for tumor immunotherapy by overcoming T cell tolerance. We anticipate that the results obtained in the proposed studies will contribute to a better basic understanding of the collaboration between CD4 and CD8 T cells in the immune response to cancer, and may suggest novel approaches for protective and therapeutic immunization strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA088956-02
Application #
6489399
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Mccarthy, Susan A
Project Start
2001-01-12
Project End
2005-12-31
Budget Start
2002-01-01
Budget End
2002-12-31
Support Year
2
Fiscal Year
2002
Total Cost
$250,499
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Pathology
Type
Schools of Medicine
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Gerner, Michael Y; Mescher, Matthew F (2009) Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells. J Immunol 182:2726-37
Gerner, Michael Y; Casey, Kerry A; Mescher, Matthew F (2008) Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol 181:155-64
Mescher, Matthew F; Popescu, Flavia E; Gerner, Michael et al. (2007) Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors. Semin Cancer Biol 17:299-308
Curtsinger, Julie M; Gerner, Michael Y; Lins, Debra C et al. (2007) Signal 3 availability limits the CD8 T cell response to a solid tumor. J Immunol 178:6752-60
Goldberg, Jodi; Shrikant, Protul; Mescher, Matthew F (2003) In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen). J Immunol 170:228-35
Shrikant, Protul; Mescher, Matthew F (2002) Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis. J Immunol 169:1753-9